一种与钠-葡萄糖协同转运蛋白2抑制剂联合使用的有效胰岛素疗法。 - Suppr

Suppr

超能文献

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors.

作者信息

Yanai Hidekatsu, Adachi Hiroki, Hakoshima Mariko, Katsuyama Hisayuki

机构信息

Department of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Japan.

出版信息

J Clin Med Res. 2019 Jan;11(1):76-79. doi: 10.14740/jocmr3676. Epub 2018 Dec 3.

DOI:10.14740/jocmr3676

PMID:30627282

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6306135/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7711/6306135/ca0c18ff8769/jocmr-11-01-076-g001.jpg

相似文献

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors.一种与钠-葡萄糖协同转运蛋白2抑制剂联合使用的有效胰岛素疗法。

J Clin Med Res. 2019 Jan;11(1):76-79. doi: 10.14740/jocmr3676. Epub 2018 Dec 3.

Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus.钠-葡萄糖协同转运蛋白2抑制剂与其他降糖药物联合用于治疗2型糖尿病

Indian J Endocrinol Metab. 2018 Nov-Dec;22(6):827-836. doi: 10.4103/ijem.IJEM_162_17.

The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.GLP-1 受体激动剂和 SGLT2 抑制剂在 U-500 胰岛素常规治疗患者中的作用。

Ann Pharmacother. 2019 Nov;53(11):1111-1116. doi: 10.1177/1060028019857557. Epub 2019 Jun 19.

Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.钠-葡萄糖共转运蛋白（SGLT）抑制剂联合胰岛素治疗对 1 型糖尿病成人血糖控制和安全性结局的影响：一项随机对照试验的荟萃分析。

Diabetes Metab Res Rev. 2019 Oct;35(7):e3169. doi: 10.1002/dmrr.3169. Epub 2019 May 9.

Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂：基于循证实践的2型糖尿病自然病程中使用方法

Curr Med Res Opin. 2016 May;32(5):907-19. doi: 10.1185/03007995.2016.1151774. Epub 2016 Feb 26.

Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.钠-葡萄糖协同转运蛋白2抑制剂依帕列净与口服抗糖尿病药物联合使用对小鼠的降血糖作用

Clin Exp Pharmacol Physiol. 2015 Jan;42(1):87-93. doi: 10.1111/1440-1681.12317.

The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病管理中的作用。

Can J Diabetes. 2017 Oct;41(5):517-523. doi: 10.1016/j.jcjd.2017.08.241.

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives.2型糖尿病中钠-葡萄糖协同转运蛋白2抑制剂与胰岛素联用：临床前景

Indian J Endocrinol Metab. 2016 Jan-Feb;20(1):22-31. doi: 10.4103/2230-8210.172268.

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.钠-葡萄糖协同转运蛋白2抑制剂联合二肽基肽酶-4抑制剂治疗2型糖尿病：当前临床证据及理论依据综述

Drug Des Devel Ther. 2017 Mar 21;11:923-937. doi: 10.2147/DDDT.S121899. eCollection 2017.

Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂在 1 型糖尿病中的安全性和疗效：系统评价和荟萃分析。

Diabetes Res Clin Pract. 2018 Mar;137:83-92. doi: 10.1016/j.diabres.2018.01.004. Epub 2018 Jan 6.

引用本文的文献

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂的多器官保护作用。

Int J Mol Sci. 2021 Apr 23;22(9):4416. doi: 10.3390/ijms22094416.

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.达格列净治疗血糖控制不佳的 1 型糖尿病患者的长期疗效和安全性（DEPICT-2 研究）：一项随机对照试验的 52 周结果。

Diabetes Obes Metab. 2020 Sep;22(9):1516-1526. doi: 10.1111/dom.14060. Epub 2020 May 22.

本文引用的文献

Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.达格列净对 2 型糖尿病患者 24 小时血糖控制的影响：一项随机对照试验。

Diabetes Technol Ther. 2018 Nov;20(11):715-724. doi: 10.1089/dia.2018.0052. Epub 2018 Sep 14.

Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy.钠-葡萄糖协同转运蛋白2抑制剂可降低接受强化胰岛素治疗的2型糖尿病患者的餐时胰岛素剂量。

J Clin Med Res. 2018 Jun;10(6):493-498. doi: 10.14740/jocmr3392w. Epub 2018 Apr 13.

Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.钠-葡萄糖协同转运蛋白2抑制剂作为1型糖尿病胰岛素治疗的附加疗法：随机对照试验的系统评价和荟萃分析

Diabetes Obes Metab. 2018 Jul;20(7):1755-1761. doi: 10.1111/dom.13260. Epub 2018 Mar 25.

Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).在日本（J-STEP/INS）进行的一项为期 52 周、多中心、随机、双盲、开放标签扩展的 4 期研究中，评估托格列净作为胰岛素的附加疗法用于 2 型糖尿病患者的长期安全性和疗效。

Diabetes Obes Metab. 2018 May;20(5):1176-1185. doi: 10.1111/dom.13213. Epub 2018 Feb 11.

Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM).在接受胰岛素治疗的2型糖尿病患者中加用卡格列净的疗效：使用连续血糖监测（CGM）检查昼夜血糖模式。

Diabetes Ther. 2017 Aug;8(4):821-827. doi: 10.1007/s13300-017-0274-3. Epub 2017 Jun 23.

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes.托格列净与甘精胰岛素联合用药、在胰岛素治疗基础上加用托格列净以及胰岛素剂量增加疗法治疗血糖控制不佳的2型糖尿病的比较

J Clin Med Res. 2016 Nov;8(11):805-814. doi: 10.14740/jocmr2741w. Epub 2016 Sep 29.

Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.除胰岛素治疗外，钠-葡萄糖协同转运蛋白2抑制剂用于2型糖尿病管理：一项随机对照试验的荟萃分析

Diabetes Obes Metab. 2017 Jan;19(1):142-147. doi: 10.1111/dom.12785. Epub 2016 Sep 29.

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).恩格列净作为1型糖尿病患者胰岛素治疗的辅助药物：一项为期4周的随机、安慰剂对照试验（EASE-1）。

Diabetes Obes Metab. 2015 Oct;17(10):928-35. doi: 10.1111/dom.12494. Epub 2015 Jun 24.

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.在基础胰岛素治疗血糖控制不佳的2型糖尿病患者中加用恩格列净的影响：一项78周随机、双盲、安慰剂对照试验

Diabetes Obes Metab. 2015 Oct;17(10):936-48. doi: 10.1111/dom.12503. Epub 2015 Jul 14.

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.探索 SGLT2 抑制剂达格列净在 1 型糖尿病中的潜力：一项随机、双盲、安慰剂对照的初步研究。

Diabetes Care. 2015 Mar;38(3):412-9. doi: 10.2337/dc13-2955. Epub 2014 Sep 30.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验